About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

- The Clipboard will hold a maximum of 500 items.
- Clipboard items will be lost after eight hours of inactivity.

Display Summary Show: 100 Sort Send to Te

Items 1-12 of 12

1: Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Related

Phase II trial of ZD1839 in recurrent or metastatic squamous cell car the head and neck.
J Clin Oncol. 2003 May 15;21(10):1980-7.
PMID: 12743152 [PubMed - indexed for MEDLINE]

2: Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. Related

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1 selective oral epidermal growth factor receptor tyrosine kinase inhibi patients with five selected solid tumor types.
J Clin Oncol. 2002 Nov 1;20(21):4292-302.
PMID: 12409327 [PubMed - indexed for MEDLINE]

3: Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Related

Selective oral epidermal growth factor receptor tyrosine kinase inhib ZD1839 is generally well-tolerated and has activity in non-small-cell cancer and other solid tumors: results of a phase I trial.
J Clin Oncol. 2002 Sep 15;20(18):3815-25.
PMID: 12228201 [PubMed - indexed for MEDLINE]

4: [No authors listed] Related

OSI Pharmaceuticals, Genentech and Roche announce data from clin of Tarceva.
Expert Rev Anticancer Ther. 2001 Jun;1(1):4-5. No abstract available.
PMID: 12113131 [PubMed - indexed for MEDLINE]

5: Dittrich Ch, Greim G, Borner M, Weigang-Kohler K, Huisman H, Amelsberg A, Ehret A, Wanders J, Hanauske A, Fumoleau P. Related

Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.
Eur J Cancer. 2002 May;38(8):1072-80.
PMID: 12008195 [PubMed - indexed for MEDLINE]

6: Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK. Related

ZD1839, a selective oral epidermal growth factor receptor-tyrosine k inhibitor, is well tolerated and active in patients with solid, malignan results of a phase I trial.
J Clin Oncol. 2002 May 1;20(9):2240-50.
PMID: 11980995 [PubMed - indexed for MEDLINE]

7: Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M. Related

Letrozole is more effective neoadjuvant endocrine therapy than tamo ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary l cancer: evidence from a phase III randomized trial.
J Clin Oncol. 2001 Sep 15;19(18):3808-16.
PMID: 11559718 [PubMed - indexed for MEDLINE]

8: Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK. Related

Phase I and pharmacologic study of OSI-774, an epidermal growth fa receptor tyrosine kinase inhibitor, in patients with advanced solid ma
J Clin Oncol. 2001 Jul 1;19(13):3267-79.
PMID: 11432895 [PubMed - indexed for MEDLINE]

9: Ghosh S, Liu XP, Zheng Y, Uckun FM. Related

Rational design of potent and selective EGFR tyrosine kinase inhibit anticancer agents.
Curr Cancer Drug Targets. 2001 Aug;1(2):129-40. Review.
PMID: 12188886 [PubMed - indexed for MEDLINE]

10: Norman P. Related

OSI-774 OSI Pharmaceuticals.
Curr Opin Investig Drugs. 2001 Feb;2(2):298-304. Review.
PMID: 11816847 [PubMed - indexed for MEDLINE]

11: Bridges AJ. Related

Chemical inhibitors of protein kinases.
Chem Rev. 2001 Aug;101(8):2541-72. Review. No abstract available.
PMID: 11749388 [PubMed - indexed for MEDLINE]

12: Arteaga CL, Johnson DH. Related

Tyrosine kinase inhibitors-ZD1839 (Iressa).
Curr Opin Oncol. 2001 Nov;13(6):491-8. Review.
PMID: 11673690 [PubMed - indexed for MEDLINE]

Display Summary Show: 100 Sort Send to Te

Items 1-12 of 12

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 10	PROUSDDR now available on STN
NEWS 4	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS 5	May 12	EXTEND option available in structure searching
NEWS 6	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 7	May 17	FRFULL now available on STN
NEWS 8	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 9	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 10	May 27	Explore APOLLIT with free connect time in June 2004
NEWS 11	Jun 22	STN Patent Forums to be held July 19-22, 2004
NEWS 12	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 13	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:50:10 ON 06 JUL 2004

=> file reg
FILE 'REGISTRY' ENTERED AT 13:50:24 ON 06 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUL 2004 HIGHEST RN 704870-92-8
DICTIONARY FILE UPDATES: 5 JUL 2004 HIGHEST RN 704870-92-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10622787.str





chain nodes :
10 11 12 13 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
3-11 8-10 11-12 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :
3-11 4-7 5-9 7-8 8-9 8-10 11-12

```
exact bonds :
13-14
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


G1:O,S,N,[*1-*2]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  12:Atom  13:CLASS  14:CLASS



L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 13:50:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    476 TO ITERATE

100.0% PROCESSED     476 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         8212 TO    10828
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:50:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   9222 TO ITERATE

100.0% PROCESSED    9222 ITERATIONS                                  3 ANSWERS
SEARCH TIME: 00.00.01

L3            3 SEA SSS FUL L1

=> d 1-3 ide cbib pi

L3   ANSWER 1 OF 3  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   346599-84-6  REGISTRY
CN   3-Pyridinecarboxamide, N-[3-[2,3-dihydro-6-(methylamino)-2-oxo-1H-
     pyrrolo[2,3-b]pyridin-4-yl]phenyl]-6-(methylamino)- (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C21 H20 N6 O2
SR   CA
LC   STN Files:   CA, CAPLUS, USPAT2, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); USES
       (Uses)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:76886 Preparation of 4-substituted 7-azaindolin-2-ones and their use as protein kinase inhibitors. Liang, Congxin; Sun, Li; Wei, Chung Chen; Tang, Peng Cho; McMahon, Gerald; Hirth, Klaus Peter; Cui, Jingrong (Sugen, Inc., USA). PCT Int. Appl. WO 2001046196 A1 20010628, 97 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US34259 20001221. PRIORITY: US 1999-PV171288 19991221.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001046196	A1	20010628	WO 2000-US34259	20001221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1244672	A1	20021002	EP 2000-990229	20001221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002183319	A1	20021205	US 2000-741737	20001221
	US 6610688	B2	20030826		
	JP 2003518123	T2	20030603	JP 2001-547106	20001221
	US 2004053924	A1	20040318	US 2003-622787	20030721

L3 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2004 ACS on STN
RN 346599-82-4 REGISTRY
CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 4-[4-(4-fluorophenyl)-1-methyl-2-[4-(methylthio)phenyl]-1H-imidazol-5-yl]-1,3-dihydro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H19 F N4 O S
SR CA

LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:76886 Preparation of 4-substituted 7-azaindolin-2-ones and their use as protein kinase inhibitors. Liang, Congxin; Sun, Li; Wei, Chung Chen; Tang, Peng Cho; McMahon, Gerald; Hirth, Klaus Peter; Cui, Jingrong (Sugen, Inc., USA). PCT Int. Appl. WO 2001046196 A1 20010628, 97 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US34259 20001221. PRIORITY: US 1999-PV171288 19991221.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001046196	A1	20010628	WO 2000-US34259	20001221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1244672	A1	20021002	EP 2000-990229	20001221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002183319	A1	20021205	US 2000-741737	20001221
	US 6610688	B2	20030826		
	JP 2003518123	T2	20030603	JP 2001-547106	20001221
	US 2004053924	A1	20040318	US 2003-622787	20030721

L3 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2004 ACS on STN
RN 346599-64-2 REGISTRY
CN 1H-Pyrrole-2-carboxamide, 5-[[4-[(3-chloro-4-fluorophenyl)amino]-1,2-dihydro-2-oxo-3H-pyrrolo[2,3-b]pyridin-3-ylidene]methyl]-4-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H26 Cl F N6 O3
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:76886 Preparation of 4-substituted 7-azaindolin-2-ones and their use as protein kinase inhibitors. Liang, Congxin; Sun, Li; Wei, Chung Chen; Tang, Peng Cho; McMahon, Gerald; Hirth, Klaus Peter; Cui, Jingrong (Sugen, Inc., USA). PCT Int. Appl. WO 2001046196 A1 20010628, 97 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US34259 20001221. PRIORITY: US 1999-PV171288 19991221.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001046196	A1	20010628	WO 2000-US34259	20001221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1244672	A1	20021002	EP 2000-990229	20001221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002183319	A1	20021205	US 2000-741737	20001221
	US 6610688	B2	20030826		
	JP 2003518123	T2	20030603	JP 2001-547106	20001221
	US 2004053924	A1	20040318	US 2003-622787	20030721

=>
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:.
STN INTERNATIONAL LOGOFF AT 13:52:25 ON 06 JUL 2004

L Number	Hits	Search Text	DB	Time stamp
1	1368	((514/300) or (546/113)).CCLS.	USPAT; US-PGPUB	2004/07/06 14:02
2	28	(((514/300) or (546/113)).CCLS.) and ("pyrrolo[2,3-b]pyridin" OR "pyrrolo[2,3-b]" OR "[2,3-b]pyridin" OR "pyrrolo(2,3-b)pyridin" OR "pyrrolo(2,3-b)" OR "(2,3-b)pyridin" OR "[2,3-b]" OR "(2,3-b)" OR "2,3-b")	USPAT; US-PGPUB	2004/07/06 14:06